Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report ; volume:13 ; number:3 ; year:2020 ; pages:1059-1066
Case reports in oncology ; 13, Heft 3 (2020), 1059-1066
- Creator
-
Nguyen, Olav Toai Duc
Sundstrøm, Stein Harald
Westvik, Ganna Surzhykova
Røttereng, Ane Karoline Stræte
Melhus, Mona Røli
Bergseth, Cecilie
Hallem, Elisabeth Kvelstad
Røe, Oluf Dimitri
- DOI
-
10.1159/000509747
- URN
-
urn:nbn:de:101:1-2021011323231010011164
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nguyen, Olav Toai Duc
- Sundstrøm, Stein Harald
- Westvik, Ganna Surzhykova
- Røttereng, Ane Karoline Stræte
- Melhus, Mona Røli
- Bergseth, Cecilie
- Hallem, Elisabeth Kvelstad
- Røe, Oluf Dimitri
Other Objects (12)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Refractory overactive bladder: a common problem?
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Pembrolizumab
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pityriasis Lichenoides et Varioliformis Acuta Developing during Pembrolizumab Treatment for Bladder Cancer
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Refractory overactive bladder: a common problem?
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Pembrolizumab
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pityriasis Lichenoides et Varioliformis Acuta Developing during Pembrolizumab Treatment for Bladder Cancer
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Refractory overactive bladder: a common problem?
Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis
Pembrolizumab
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pityriasis Lichenoides et Varioliformis Acuta Developing during Pembrolizumab Treatment for Bladder Cancer
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression